On December 30, 2020, volunteers prepared doses of the Moderna COVID-19 vaccine at Forand Manor in Central Falls, RI.
Boston Globe | Boston Globe | Getty Images
The European Medicines Agency recommended Moderna’s coronavirus vaccine for use in the European Union, at a time when criticism is growing about the slow rollout of bumps across the block.
“The EMA’s Human Medicine Committee has thoroughly reviewed the data on the quality, safety and efficacy of the vaccine and, by consensus, recommends that a formal conditional marketing authorization be granted by the European Commission,” the EMA said in a statement.
Emer Cooke, executive director of the Amsterdam EMA, added that Moderna’s vaccine ‘offers us another tool to overcome the current emergency’. This paves the way for the European Commission, the executive arm of the EU, to follow their example.
Moderna’s vaccine is the second to be relieved by European regulators, but vaccinations have already been distributed in the UK and in the US, where it was previously approved.
Some legislators have expressed concern that the EU is spreading too slowly with the vaccination of coronavirus among its citizens.
The deployment of Covid-19 jabs varies across the block. France reported 516 vaccinations in the first week of its implementation, while Germany had about 240,000 vaccinations as of Sunday. The Netherlands has not yet started vaccinating people against the coronavirus.
In addition, there are questions about whether the EU has bought enough vaccines.
A number of officials have asked the European Commission, the EU’s executive, to explain why it did not buy more pipe pipes.
A European Commission spokesman said on Monday that the institution “is very much focused on ensuring that the implementation of our strategy is done well.”
Following the announcement, Moderna’s shares rose slightly in pre-market trading.